Evidence Level
Preliminary
Calcium D-glucarate's primary mechanism — beta-glucuronidase inhibition — is well-established in biochemistry and supported by animal studies. Walaszek et al. (1997) demonstrated that D-glucarate supplementation inhibited beta-glucuronidase activity and reduced tumor incidence in animal models of breast, colon, and liver cancer. Hanausek et al. (2003) further characterized the anti-proliferative mechanisms. However, rigorous human clinical trials specifically for calcium D-glucarate in estrogen metabolism or cancer prevention are lacking. The supplement's popularity is largely based on the well-characterized biochemistry, animal data, and logical extrapolation to human estrogen metabolism rather than direct human RCT evidence.